GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Capex-to-Operating-Cash-Flow

Xvivo Perfusion AB (Xvivo Perfusion AB) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Xvivo Perfusion AB's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $0.15 Mil.

Hence, Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 0.00.


Xvivo Perfusion AB Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Capex-to-Operating-Cash-Flow Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.84 - - 4.70 3.11

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow

For the Medical Devices subindustry, Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow falls into.



Xvivo Perfusion AB Capex-to-Operating-Cash-Flow Calculation

Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-14.032) / 4.512
=3.11

Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0.153
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (OTCPK:XVIPF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Xvivo Perfusion AB Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.